Literature DB >> 23410547

Patient- and trial-specific barriers to participation in cardiovascular randomized clinical trials.

Seth S Martin1, Fang-Shu Ou, L Kristin Newby, Victoria Sutton, Patricia Adams, G Michael Felker, Tracy Y Wang.   

Abstract

OBJECTIVES: The purpose of this study was to quantitatively examine the association of patient- and trial-specific factors with participation in cardiovascular randomized clinical trials.
BACKGROUND: Randomized clinical trials are central to evidenced-based medicine, but low patient participation rates and potentially modifiable barriers are not well understood.
METHODS: At a large U.S. academic health system, we examined screening logs from December 1, 2005, to February 28, 2011, from 15 cardiovascular randomized clinical trials. We identified 655 patients who were screened and potentially eligible for participation in at least 1 trial. We used multivariable Poisson regression to quantify the risk of not participating in a trial associated with patient- and trial-specific factors.
RESULTS: The median age was 63 years (interquartile range: 54 to 72), 35% were women, and the median Charlson Index was 2 (interquartile range: 1 to 5). Forty-two percent of patients did not participate in a trial. In multivariable regression (C-Index 0.85), trial-specific factors strongly associated with not participating included intensive trial-related testing (relative risk [RR]: 1.89; 95% confidence interval [CI]: 1.63 to 2.20) and anticipated trial participation >6 months (RR: 4.10; 95% CI: 2.30 to 7.29). Patient-specific factors associated with not participating included older age (RR: 1.23; 95% CI: 1.11 to 1.36, per 10-year increase if age ≥65 years), out-of-state residence (RR: 1.26; 95% CI: 1.04 to 1.54), and female sex (RR: 1.17; 95% CI: 1.01 to 1.35). Race was not associated with participation.
CONCLUSIONS: While patient-specific factors were associated with not participating in cardiovascular trials, longer trial duration and intensive trial-related testing were most strongly associated with risk for patients not participating. Innovative trial designs fostering convenience may most enhance trial participation.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23410547     DOI: 10.1016/j.jacc.2012.10.046

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  23 in total

Review 1.  Good Clinical Practice Guidance and Pragmatic Clinical Trials: Balancing the Best of Both Worlds.

Authors:  Robert J Mentz; Adrian F Hernandez; Lisa G Berdan; Tyrus Rorick; Emily C O'Brien; Jenny C Ibarra; Lesley H Curtis; Eric D Peterson
Journal:  Circulation       Date:  2016-03-01       Impact factor: 29.690

Review 2.  Why are sex and gender important to basic physiology and translational and individualized medicine?

Authors:  Virginia M Miller
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-01-10       Impact factor: 4.733

Review 3.  Global geographical variation in patient characteristics in percutaneous coronary intervention clinical trials: A systematic review and meta-analysis.

Authors:  Eden Liu; Leon Hsueh; Hajwa Kim; Mladen I Vidovich
Journal:  Am Heart J       Date:  2017-09-08       Impact factor: 4.749

4.  Understanding factors contributing to participant satisfaction in stroke walking recovery clinical trials.

Authors:  Mark Cummings; Sonia Pradhan; Sangeetha Madhavan
Journal:  Contemp Clin Trials Commun       Date:  2022-06-11

5.  Non-oncology clinical trial engagement in a nationally representative sample: Identification of motivators and barriers.

Authors:  Zachary Feuer; Richard S Matulewicz; Ramsankar Basak; Donna A Culton; Kimberly Weaver; Kristalyn Gallagher; Tracy L Rose; Matthew Milowsky; Marc A Bjurlin
Journal:  Contemp Clin Trials       Date:  2022-02-22       Impact factor: 2.261

6.  Willingness to Participate in Cardiovascular Clinical Research among African-Americans.

Authors:  P Stuchlik; X Zhang; S Gavin; S Gaudreau; J L Breault; L A Bazzano
Journal:  J Clin Res Bioeth       Date:  2015-06

7.  Engaging heart failure patients from a clinical data research network: A survey on willingness to participate in different types of research.

Authors:  Yong K Choi; Javier E López; Daniella Meeker; Lucila Ohno-Machado; Katherine K Kim
Journal:  AMIA Annu Symp Proc       Date:  2020-03-04

8.  Representativeness of a Heart Failure Trial by Race and Sex: Results From ASCEND-HF and GWTG-HF.

Authors:  Stephen J Greene; Adam D DeVore; Shubin Sheng; Gregg C Fonarow; Javed Butler; Robert M Califf; Adrian F Hernandez; Roland A Matsouaka; Ayman Samman Tahhan; Kevin L Thomas; Muthiah Vaduganathan; Clyde W Yancy; Eric D Peterson; Christopher M O'Connor; Robert J Mentz
Journal:  JACC Heart Fail       Date:  2019-10-09       Impact factor: 12.035

Review 9.  Sex-Specific Outcomes in Cardiovascular Device Evaluations.

Authors:  Mohammed Imran Ghare; Daniela Tirziu; Jinnette Dawn Abbott; Elissa Altin; Yiping Yang; Vivian Ng; Cindy Grines; Alexandra Lansky
Journal:  J Womens Health (Larchmt)       Date:  2020-06-15       Impact factor: 3.017

10.  ClinicalTrials.gov as a data source for semi-automated point-of-care trial eligibility screening.

Authors:  Pascal B Pfiffner; JiWon Oh; Timothy A Miller; Kenneth D Mandl
Journal:  PLoS One       Date:  2014-10-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.